Sanaz Memarzadeh

Lymphovascular and perineural invasion in the parametria: a prognostic factor for early-stage cervical cancer.

Non-Peutz-Jeghers syndrome associated ovarian sex cord tumor with annular tubules: a case report.

Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium.

Role of autonomous androgen receptor signaling in prostate cancer initiation is dichotomous and depends on the oncogenic signal.

Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo.

Tubal Ligation Induces Quiescence in the Epithelia of the Fallopian Tube Fimbria.

A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas.

Expression of Stromal Progesterone Receptor and Differential Methylation Patterns in the Endometrium May Correlate with Response to Progesterone Therapy in Endometrial Complex Atypical Hyperplasia.

Retraction Note: An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer.

An asymptomatic anterior vaginal wall endometrioma, a rare manifestation of endometriosis: A case report.

Ga-FAPi-46 diffuse bilateral breast uptake in a patient with cervical cancer after hormonal stimulation.

Exploring the Potential of Drug Response Assays for Precision Medicine in Ovarian Cancer.

Matched sequential tumor molecular profiling in solid malignancies may impact clinical practice.

Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy.

Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy.

Gynecologic tumor board: a radiologist's guide to vulvar and vaginal malignancies.

A rare case of vulvar extraskeletal myxoid chondrosarcoma: mimics and diagnostic clues.

Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers.

Management of Clitoral Melanoma Presenting as an Exophytic Clitoral Mass: A Case Report and Review of the Literature.

cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution.

Efficacy of birinapant in combination with carboplatin in targeting platinum‑resistant epithelial ovarian cancers.

Inability of ovarian cancers to upregulate their MHC-class I surface expression marks their aggressiveness and increased susceptibility to NK cell-mediated cytotoxicity.

Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors.

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.

Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival.

Androgen receptor and its correlation with estrogen and progesterone receptors, aimed for identification of cases for future anti-androgen therapy in endometrial cancers.

Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design.

Percutaneous interstitial brachytherapy ablation for targeting oligometastatic gynecologic cancers.

Exploring the Potential of Natural Killer Cell-Based Immunotherapy in Targeting High-Grade Serous Ovarian Carcinomas.

PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity.